The First KRAS Drugs Have Been Sluggish on the Market. Will the Next Generation Fare Better?

Why It Matters

The next wave of KRAS inhibitors could dramatically broaden treatment options for lung, colorectal and pancreatic cancers, while reshaping a fast‑growing, high‑stakes oncology market.

Key Takeaways

• Lumakras 2025 Q4 sales $92M, 8% YoY growth.
• KRAS G12C inhibitors respond in only 30‑40% patients.
• Second‑gen drugs target KRAS G12D and G12V mutations.
• Amgen developing pan‑KRAS inhibitor AMG 410.
• Market projected $3‑4 B by 2028, intense competition.

Pulse Analysis

The approval of Lumakras in 2021 marked a watershed moment, proving that the once‑undruggable KRAS protein could be inhibited. By exploiting a previously hidden pocket, Amgen delivered a therapy for KRAS G12C‑mutated non‑small cell lung cancer and certain colorectal cancers. Yet commercial traction has been limited; a niche patient pool, reimbursement hurdles, and modest response rates—roughly 30‑40%—have kept revenues modest despite steady growth. This reality underscores the need for broader, more effective KRAS strategies.

Industry momentum now centers on second‑generation inhibitors that expand beyond the G12C variant. Companies such as Roche, Merck and Lilly are advancing G12C agents with higher response rates and longer progression‑free survival, while early‑stage programs target the more prevalent G12D and G12V mutations found in pancreatic and colorectal tumors. Amgen’s pan‑KRAS candidate AMG 410 aims to hit multiple KRAS isoforms, and Revolution Medicines’ multi‑selective daraxonrasib seeks to block several RAS variants simultaneously. Parallel combination trials—pairing KRAS inhibitors with EGFR antibodies, chemotherapy or immunotherapy—are designed to overcome adaptive resistance and deepen clinical benefit.

The market outlook is bullish but competitive. Forecasts suggest a $3‑4 billion KRAS inhibitor market by 2028, contingent on new drugs proving superior durability, safety and cost‑effectiveness. Payers will scrutinize pricing against incremental survival gains, especially as combination regimens drive up therapy complexity. For patients, the expanding toolbox promises earlier‑line options and tailored treatments for hard‑to‑treat cancers, with colorectal cancer poised as the fastest‑growing segment. Success of the next generation could redefine KRAS as a cornerstone of precision oncology.